90R3011 LRM-F By: Miles S.B. No. 352 A BILL TO BE ENTITLED AN ACT relating to establishment of the Texas Rare Disease Advisory Council. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. Subtitle E, Title 2, Health and Safety Code, is amended by adding Chapter 101B to read as follows: Added text: CHAPTER 101B. TEXAS RARE DISEASE ADVISORY COUNCIL (End of added text) Added text: Sec. 101B.001. DEFINITIONS. In this chapter: (End of added text) Added text: (1) "Advisory council" means the Texas Rare Disease Advisory Council established under this chapter. (End of added text) Added text: (2) "Institution of higher education" means an institution of higher education or a private or independent institution of higher education, as those terms are defined by Section 61.003, Education Code. (End of added text) Added text: Sec. 101B.002. ESTABLISHMENT OF ADVISORY COUNCIL. (a) The Texas Rare Disease Advisory Council is established to advise the legislature, the governor, state agencies, and private entities that provide services or care to individuals with rare diseases in this state on the needs of those individuals. (End of added text) Added text: (b) The department shall designate an institution of higher education in this state on agreement of the institution to provide administrative support to the advisory council in discharging duties under this chapter. (End of added text) Added text: Sec. 101B.003. ADVISORY COUNCIL MEMBERS. (a) The advisory council is composed of: (End of added text) Added text: (1) one representative of the institution of higher education providing administrative support under Section 101B.002, appointed by the president of the institution; (End of added text) Added text: (2) one representative of the department, appointed by the commissioner; (End of added text) Added text: (3) one representative of the commission whose duties involve the medical assistance program under Chapter 32, Human Resources Code, appointed by the executive commissioner; (End of added text) Added text: (4) one representative of the Texas Department of Insurance, appointed by the commissioner of insurance; and (End of added text) Added text: (5) the following members, appointed by majority vote of the members of the advisory council described by Subdivisions (1)-(4): (End of added text) Added text: (A) one geneticist licensed and practicing in this state; (End of added text) Added text: (B) one registered nurse or advanced practice registered nurse licensed and practicing in this state with experience treating rare diseases; (End of added text) Added text: (C) one physician licensed and practicing in this state with experience treating rare diseases; (End of added text) Added text: (D) one hospital administrator, or the hospital administrator's designee, of a hospital in this state that provides care to individuals diagnosed with a rare disease; (End of added text) Added text: (E) at least two individuals with a rare disease; (End of added text) Added text: (F) at least one caregiver of an individual with a rare disease; (End of added text) Added text: (G) one representative of a rare disease patient organization that operates in this state; (End of added text) Added text: (H) one pharmacist with experience dispensing drugs used to treat rare diseases; (End of added text) Added text: (I) one representative of the biopharmaceutical industry; (End of added text) Added text: (J) one representative of a health insurance company; and (End of added text) Added text: (K) one member of the scientific community who is engaged in rare disease research, including a medical researcher with experience conducting research on rare diseases. (End of added text) Added text: (a-1) Notwithstanding Subsection (a) and not later than December 1, 2027, the initial members of the advisory council shall be appointed as follows: (End of added text) Added text: (1) the appropriate appointing authority shall appoint the members described by Subsections (a)(1)-(4); and (End of added text) Added text: (2) the initial presiding officer of the advisory council appointed under Section 101B.004(b-1) shall appoint the members described by Subsection (a)(5). (End of added text) Added text: (a-2) This subsection and Subsection (a-1) expire September 1, 2033. (End of added text) Added text: (b) Except as otherwise provided by Subsection (c), an individual must be a resident of this state to be eligible for appointment as a member of the advisory council. (End of added text) Added text: (c) The representative of the biopharmaceutical industry appointed under Subsection (a)(5)(I) may be a resident of any state. (End of added text) Added text: (d) If a vacancy occurs on the advisory council, the appropriate appointing authority shall, in a timely manner and in compliance with the requirements of this section, appoint a successor to serve for the remainder of the unexpired term. (End of added text) Added text: (e) The advisory council shall conduct the member appointment process in a transparent manner to provide interested individuals an opportunity to apply for membership on the advisory council. (End of added text) Added text: Sec. 101B.004. PRESIDING OFFICER. (a) Members of the advisory council shall select from among the advisory council's members a presiding officer. (End of added text) Added text: (b) An individual who holds an elected or appointed state governmental position or a state employee may not be appointed as the presiding officer of the advisory council. (End of added text) Added text: (b-1) Notwithstanding Subsection (a) or Section 101B.005(b) and not later than October 1, 2027, the governor, or the governor's designee, shall appoint an initial presiding officer of the advisory council. This subsection expires September 1, 2033. (End of added text) Added text: Sec. 101B.005. TERMS. (a) Members of the advisory council serve staggered three-year terms, with the terms of one-third of the members, or as near to one-third as possible, expiring each year. (End of added text) Added text: (a-1) Notwithstanding Subsection (a), an initial advisory council member appointed under Section 101B.003(a-1) may serve a two-year, three-year, or four-year term. This subsection expires September 1, 2033. (End of added text) Added text: (b) The presiding officer of the advisory council serves a two-year term. (End of added text) Added text: (b-1) Notwithstanding Subsection (b), the initial presiding officer of the advisory council appointed under Section 101B.004(b-1) serves a three-year term. This subsection expires September 1, 2033. (End of added text) Added text: Sec. 101B.006. DUTIES. The advisory council shall: (End of added text) Added text: (1) consult with experts on rare diseases to develop policy recommendations for improving patient access to: (End of added text) Added text: (A) rare disease specialists; (End of added text) Added text: (B) affordable and comprehensive health care coverage; (End of added text) Added text: (C) relevant diagnostic procedures for rare diseases; (End of added text) Added text: (D) timely and quality treatment for rare diseases; and (End of added text) Added text: (E) other needed services, as determined by the advisory council; (End of added text) Added text: (2) make recommendations to state agencies and insurers that provide services to individuals with a rare disease on the impact on treatment provision for the individual of prior authorization requirements, cost-sharing requirements, benefits tiering, or other utilization management procedures; (End of added text) Added text: (3) make recommendations to improve coverage under the state Medicaid program of drugs for rare disease patients, including engagement with the Drug Utilization Review Board, to improve health benefit plan coverage of diagnostic procedures, and to facilitate access to necessary health care providers with expertise in the treatment of rare diseases; (End of added text) Added text: (4) identify best practices to reduce health disparities and achieve health equity in the research, diagnosis, and treatment of rare diseases in this state; and (End of added text) Added text: (5) identify best practices to ensure continuity of care for rare disease patients transitioning from pediatric to adult care. (End of added text) Added text: Sec. 101B.007. BIENNIAL REPORT. (a) Not later than September 1 of each even-numbered year, the advisory council shall prepare and submit a report on the advisory council's activities, funding, and legislative recommendations to the governor, department, and standing committees of the senate and house of representatives with primary jurisdiction over health care and appropriations. (End of added text) Added text: (b) Before finalizing and submitting the report under Subsection (a), a draft of the report must be made available for public comment and discussion at a meeting open to the public. (End of added text) Added text: Sec. 101B.008. FUNDING. The advisory council may solicit and accept gifts, grants, and donations from any source to establish and operate the advisory council. (End of added text) Added text: Sec. 101B.009. ADVISORY COUNCIL MEETINGS. (a) The advisory council shall meet at least once each quarter. (End of added text) Added text: (b) A meeting conducted under this section may be in person or by video conference call, as determined by the presiding officer. (End of added text) Added text: (c) Not later than January 1, 2028, the advisory council shall hold an initial meeting. During the 2028 calendar year, the advisory council shall meet at least once per month. This subsection expires September 1, 2029. (End of added text) Added text: Sec. 101B.010. PUBLIC OUTREACH. The advisory council shall: (End of added text) Added text: (1) provide opportunities to inform the public about the advisory council's work and for the public to provide comments on that work; and (End of added text) Added text: (2) create and maintain a public Internet website to: (End of added text) Added text: (A) provide public access to meeting minutes; (End of added text) Added text: (B) provide notice of upcoming advisory council meetings; and (End of added text) Added text: (C) allow for the submission of public comments. (End of added text) SECTION 2. This Act takes effect September 1, 2027.
← Back to SB 352
SB 352 · Version I
Introduced
Dated Nov 13, 2026
Underlined: added by this bill. Struck through: removed by this bill. Plain words stay as they are.